Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK102 in Homozygous Familial Hypercholesterolemia
CTR20190533Phase 2Active
- Sponsor
- Kangrong Oriental
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ebronucimab in familial hypercholesterolemia (FH), sponsored by Kangrong Oriental. Started Mar 2019; status: active.
02
Drugs
ebronucimab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on CTR20190533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190533.